.
MergerLinks Header Logo

New Deal


Announced

Novozymes to acquire a majority stake in Synergia Life Sciences for $150m.

Financials

Edit Data
Transaction Value£112m
Consideration TypeCash
Capital Owned-
Capital Bid For60%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

India

Cross Border

Private

Friendly

Majority

Pharmaceuticals

pharmaceutical company

Original Bidder Won

Acquisition

Pending

Synopsis

Edit

Novozymes, a provider of biological solutions, agreed to acquire a majority stake in Synergia Life Sciences, a manufacturer of chemicals and chemical products, pharmaceuticals and botanical products, for $150m. "Novozymes’ strong presence in the functional foods and dietary supplement space makes this a strategic fit for Synergia’s innovative product portfolio. We are very excited to be part of the Novozymes family," Dilip Mehta, Synergia Life Sciences CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US